Aciphin 250 mg Dry Powder for injection: Each vial contains Ceftriaxone Sodium USP equivalent to 250 mg Ceftriaxone for both IV & IM administration.
Aciphin 500 mg Dry Powder for injection: Each vial contains Ceftriaxone Sodium USP equivalent to 500 mg Ceftriaxone for both IV & IM administration.
Aciphin 1 g Dry Powder for injection: Each vial contains Ceftriaxone Sodium USP equivalent to 1 g Ceftriaxone for both IV & IM administration.
Aciphin 2 g Dry Powder for injection: Each vial contains Ceftriaxone Sodium USP equivalent to 2 g Ceftriaxone for IV administration.
Aciphin is a preparation of Ceftriaxone Sodium which is bactericidal, long-acting, broad spectrum, parenteral cephalosporin preparation, active against a wide range of gram positive and gram negative susceptible microorganisms. Aciphin acts by inhibition of bacterial cell wall synthesis. Aciphin has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Route: Intramuscular (IM) / Intravenous (IV)
Adults and children >12 years:
1–2 g once daily (every 24 hours); 2–4 g daily in severe infections. Single IV doses >1 g by IV infusion only.
Children (15 days to 12 years):
20–50 mg/kg once daily (up to 80 mg/kg in severe infections; doses ≥50 mg/kg by IV infusion over ≥30 minutes).
Neonates (up to 14 days):
20–50 mg/kg IV infusion over 60 minutes once daily (maximum 50 mg/kg). Children ≥50 kg: adult dosage.
Special Indications:
Renal & Hepatic adjustments:
Concomitant administration with intravenous calcium-containing solutions is contraindicated due to crystalline precipitation in lungs and kidneys; enhances anticoagulant effect of vitamin K antagonists (warfarin); aminoglycosides exhibit synergistic nephrotoxicity.
Ceftriaxone is contraindicated in patients with a known hypersensitivity to ceftriaxone or any components of this product. It is also contraindicated in premature infants.
Less Common: Nausea, vomiting, diarrhea, dizziness, fever, involuntary movements, convulsions. Rare: Prolongation of prothrombin time, pancreatitis.
Overdose
In the case of overdose, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic.
Category B. Safety during pregnancy has not been established; contraindicated in first trimester unless clearly needed and clinically essential. Lactation: Ceftriaxone is excreted in breast milk in low concentrations; use with caution in nursing mothers.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.